Saama Introduces Modular and Adaptive AI Agents for Clinical Innovation

CAMPBELL, Calif., Sept. 29, 2025 /PRNewswire/ -- Saama, an established leader in AI-driven solutions and services within Health Sciences, is introducing industry-first modular Clinical AI Agents to help sponsors drive rapid innovation and efficiencies on existing platform investments from Study Start to Submission. Developed using Saama's state-of-the-art Agentic AI platform, these Clinical Agents are designed to function on "partial autonomy," that enable appropriate human oversight and controls. Saama's Clinical AI Agents are capable of extensive independent reasoning, planning, and execution. They offer adaptability, tailored customization, and seamless integration with the Saama Digital Study Platform or any existing platforms and systems, driving efficiencies across the clinical development value chain through submission and beyond.

Saama's Agentic innovation is a highly adaptive and compliant solution, whose need is underscored by a recent Massachusetts Institute of Technology (MIT) report showing that 95% of enterprise generative AI pilots fail due to poor integration, limited adaptability, and generic tools not being able to manage complex workflows. In clinical development, where data integrity and compliance are paramount, this failure rate highlights the risk of relying on generalist models without appropriate clinical calibration. 

Purpose-built for life sciences, the Agentic AI Clinical Agents address these challenges with a modular framework that allows customers to deploy individual agents or complete agentic workflows. The power of the ecosystem is the capability to additionally design bespoke agents for distinct needs and leverage continuous training for ongoing improvement—all with the crucial human-in-the-loop oversight.

"Saama has been at the forefront of transforming healthcare and life sciences with AI for over a decade," said Bhaskar Sambasivan, Chief Executive Officer of Saama. "By introducing these AI Agents, backed by a modular framework, we enable our customers to engage in rapid innovation on top of their existing platform investments, accelerating time and reducing effort and costs." 

"Our platform's embedded agents go far beyond traditional automation," said Prasanna Rao, Chief Products and Innovation Officer at Saama. "They reason, learn, and act within clinical contexts and collaborate with humans-in-the-loop to help achieve complex goals. With our focus on compliant and responsible AI, we are overcoming the barriers that have stalled most enterprise AI initiatives and setting a new standard for clinical development."

For more information, visit www.saama.com or sign up for Saama's October 30 webinar on Agentic AI here.

About Saama
Saama develops healthcare and life science products and solutions that accelerate the delivery of therapies to patients. Saama also provides specialized data, analytics, and AI services to other industries. The company's AI-driven clinical data management platform enables pharma and biotech companies to streamline clinical and commercial operations, improve data quality and access, and gain faster insights across their clinical trials. The Saama platform powered the clinical trial that led to the world's first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/saama-introduces-modular-and-adaptive-ai-agents-for-clinical-innovation-302569786.html

SOURCE Saama